SCHEMBL10136670

SCHEMBL10136670

COC(=O)c1cc(F)cc2c1nc(Cl)c1cnccc12

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 11/20 0.49
PIM2 Q9P1W9 11/20 0.49
CSNK2A1 P68400 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
AXL P30530 1/20 0.38
BAD Q92934 6/20 0.38
FLT3 P36888 3/20 0.38
PARP1 P09874 1/20 0.37
PIM3 Q86V86 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10136651 0.95 PIM1 (0.52) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL10136673 0.81 PIM1 (0.63) PIM1PIM2KDM4EALDH1A1GLA
SCHEMBL28786457 0.78 KDM4E (0.50) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL2688734 0.77 PIM1 (0.66) PIM1PIM2KDM4EALDH1A1GLA
SCHEMBL10136643 0.74 PARP1 (0.50) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL2690184 0.72 CSNK2A2 (0.68) PIM1PIM2CSNK2A1CSNK2A2CSNK2B
SCHEMBL10136628 0.71 PARP1 (0.56) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL28892677 0.71 KDM4E (0.51) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL28892356 0.71 KDM4E (0.51) PIM1PIM2CSNK2A1L3MBTL1KDM4E
SCHEMBL528759 0.70 KDM4E (0.40) CSNK2A1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885CSNK2A1 680/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885CSNK2A1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.